36 patents
Utility
Isoform-specific, Context-permissive TGFB1 Inhibitors and Use Thereof
18 Jan 24
Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation.
Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
Filed: 1 Aug 23
Utility
Use of Anti-pro/latent Myostatin Antibody for Treating Spinal Muscular Atrophy
4 Jan 24
The present disclosure relates to therapeutic methods, uses, and compositions comprising an anti-pro/latent myostatin antibody to treat spinal muscular atrophy (SMA) in human subjects, either as monotherapy or as an adjunct to a motor neuron-directed therapy, such as an SMN upregulator/corrector therapy.
George NOMIKOS, Guochen SONG, Ryan IARROBINO, Yung CHYUNG
Filed: 25 Oct 21
Utility
Compositions and methods for growth factor modulation
28 Nov 23
Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities.
Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Straub
Filed: 9 Mar 21
Utility
TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF
2 Nov 23
Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGFβ1, LTBP1-TGFβ1, LTBP3-TGFβ1, and/or LRRC33-TGFβ1.
Thomas SCHURPF, Gregory J. CARVEN, Abhishek DATTA, Kimberly LONG
Filed: 31 Mar 23
Utility
TGFβ1-binding immunoglobulins and use thereof
9 May 23
Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGFβ1, LTBP1-TGFβ1, LTBP3-TGFβ1, and/or LRRC33-TGFβ1.
Thomas Schurpf, Gregory J. Carven, Abhishek Datta, Kimberly Long
Filed: 10 Mar 17
Utility
TGFB Inhibitors and Use Thereof
23 Feb 23
Disclosed herein are novel inhibitors of TGFβ1 activation with durable inhibitory effects.
Stefan Wawersik, Thomas Schurpf, Christopher Chapron, Sandeep Kumar, Adam Fogel
Filed: 11 Jan 21
Utility
Tgf-beta Inhibitors and Use Thereof
16 Feb 23
The present disclosure provides TGFβ inhibitor therapy for treating immunosuppressive conditions, such as cancer.
Ashish Kalra, Thomas Schurpf, Adam Fogel, Christopher Brueckner, Alan Buckler, Constance Martin, Si Tuen Lee-Hoeflich
Filed: 11 Jan 21
Utility
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
17 Nov 22
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ.
Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, JR.
Filed: 17 May 22
Utility
Methods for using anti-myostatin antibodies
13 Sep 22
Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
Gregory J. Carven, Michelle Straub, Adriana Donovan, Katherine Jane Turner
Filed: 24 Jun 20
Utility
LTBP complex-specific inhibitors of TGFβ and uses thereof
21 Jun 22
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ.
Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
Filed: 19 Nov 21
Utility
Isoform-selective TGFB1 Inhibitors and Use Thereof
3 Mar 22
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency.
Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
Filed: 19 Aug 21
Utility
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
3 Mar 22
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ.
Thomas SCHURPF, Justin W. JACKSON, George CORICOR, Abhishek DATTA, Stefan WAWERSIK, Christopher LITTLEFIELD, Adam FOGEL, Caitlin STEIN, Julia McCREARY, Matthew SALOTTO, Frederick STREICH, JR.
Filed: 19 Nov 21
Utility
LTBP complex-specific inhibitors of TGFβ and uses thereof
4 Jan 22
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ.
Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
Filed: 19 Aug 20
Utility
Rgmc-selective Inhibitors and Use Thereof
9 Dec 21
Selective inhibitors of repulsive guidance molecule C (RGMc), are described.
Samantha Nicholls, Adriana Donovan, Meghan McDonald, Abhishek Datta, Allan Capili, Kevin B. Dagbay, Lorena Lerner, Leonard Ira Zon, Kevin Schutz, John Bukowski, Justin W. Jackson
Filed: 23 Oct 19
Utility
TGFSS1 Inhibitors and Use Thereof
4 Nov 21
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1.
Abhishek Datta, Thomas Schurpf, Allan Capili, Stefan Wawersik, Christopher Chapron, Christopher Littlefield, Gregory J. Carven, Kevin B. Dagbay, Susan Lin, Justin W. Jackson, Caitlin Stein
Filed: 11 Jul 19
Utility
Methods for Inhibiting Myostatin Activation by Administering Anti-pro/latent Myostatin Antibodies
28 Oct 21
The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
Adriana Donovan, Michelle Straub, Stefan Wawersik
Filed: 29 Oct 20
Utility
Compositions and methods for making and using anti-myostatin antibodies
26 Oct 21
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
Adriana Donovan, Stefan Wawersik, Yung Chyung, Micah Webster
Filed: 5 Jan 18
Utility
Methods for making and using anti-myostatin antibodies
5 Oct 21
Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
Michelle Straub, Dong Yun Lee, William K. McConaughy, Katherine Jane Turner, Nagesh K. Mahanthappa, Justin W. Jackson
Filed: 4 Apr 19
Utility
Isoform-selective TGFβ1 inhibitors and use thereof
28 Sep 21
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency.
Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
Filed: 11 Jul 19
Utility
Use of Myostatin Inhibitors and Combination Therapies
16 Sep 21
The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling.
Kimberly LONG, Adriana DONOVAN, Yung CHYUNG, Michelle STRAUB
Filed: 3 Feb 21